Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide

Elie G. Dib, Emmanuel S. Antonarakis, Matthew J. Wasco, Steven F. Powell

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)e365-e368
JournalClinical Genitourinary Cancer
Volume17
Issue number2
DOIs
StatePublished - Apr 2019
Externally publishedYes

Bibliographical note

Funding Information:
E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, ESSA, AstraZeneca, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol-Myers Squibb, AstraZeneca, Clovis, and Merck; and he is the coinventor of a biomarker technology that has been licensed to Qiagen. S.F.P. received research support to his institution from Merck, Bristol-Myers Squibb, Pfizer, Vyriad, Genentech, and Novartis; and he has served as a consultant for Bristol-Myers Squibb. The other authors have stated that they have no conflict of interest.

Keywords

  • CDK12
  • Checkpoint inhibitor
  • Homologous recombination
  • Mismatch-repair deficiency
  • PDL-1

Cite this